Retrospective cohort study evaluating exenatide twice daily and long-acting insulin analogs in a Veterans Health Administration population with type 2 diabetes.

导出 LinkOut

翻译打印收藏纠错

作者： M,Bounthavong ^[1] ; J N,Tran ^[2] ; S,Golshan ^[3] ; N F,Piland ^[4] ; C M,Morello ^[5] ; A,Blickensderfer ^[6] ; J H,Best ^[7]

作者单位： Veterans Affairs San Diego Healthcare System, San Diego, USA. Electronic address: mark.bounthavong@va.gov. ^[1] Clinical Analytics and Outcomes Research, OptumRX, Irvine, CA, USA. Electronic address: josephine.tran@optum.com. ^[2] Advanced Center for Innovation in Services and Intervention Research (ACISIR), University of California, Department of Psychiatry, San Diego, CA, USA. Electronic address: sgolshan@ucsd.edu. ^[3] Idaho State University, Institute of Rural Health, Pocatello, Idaho, USA. Electronic address: pilaneil@isu.edu. ^[4] UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, California, USA. Electronic address: cmmorello@ucsd.edu. ^[5] Medical Relations & Information, Amylin Pharmaceuticals, LLC., a fully-owned subsidiary of Bristol-Myers Squibb, San Diego, California, USA. Electronic address: blickpharmd@hotmail.com. ^[6] Health Outcomes, Amylin Pharmaceuticals, LLC., a fully-owned subsidiary of Bristol-Myers Squibb, San Diego, California, USA; University of Washington, Seattle, Washington, USA. Electronic address: bestj@uw.edu. ^[7]

关键词 Detemir Exenatide Glargine Long-acting insulin analogs Pharmacoepidemiology Retrospective cohort Type 2 diabetes Veterans